PDGFR

Target
  1. VEGFR2 (1)
Actions
  1. Inhibitor (15)


19 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Product Information
A15933

AC710

AC710 is a potent, orally active, and selective platelet-derived growth factor receptor-family kinase inhibitor with potential anticancer activity.
A16246

AC710 Mesylate

AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively.
A11350

CP-673451

CP 673451 is a potent PDGFR-β inhibitor with an IC50 of 1 nM.
A11052

Crenolanib (CP-868596)

Crenolanib (CP-868596) is an orally bioavailable, selective small molecule inhibitor of the PDGFR tyrosine kinase, inhibiting both PDGFRA and PDGFRB at picomolar concentrations.
A15062

DCC-2618

DCC-2618 is a small molecule inhibitor of c-Kit and PDGFR with IC50s of 6 nM/30 nM/13 nM for c-Kit/PDGFR??/PDGFR?? respectively.
A11978

Delphinidin chloride

Delphinidin chloride is an anthocyanidin, a common plant pigment, found in pigmented fruits and vegetable.
A13530

Flumatinib mesylate

Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 a and VEGF in U266 cell line in a time- and dose-dependent manners, so flumatinib mesylate may become a new drug for MM therapy.
A10504

KRN 633

KRN 633 is a cell-permeable, reversible, ATP-competitive VEGFR kinase inhibitor that inhibits PDGFR-α and c-Kit at higher concentrations only (IC50 = 0.97 μM and 4.33 μM, respectively) and inactive towards 17 other kinases (IC50 ≥ 10 μM).
A10025

Linifanib (ABT-869)

Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGFR-β, KDR, and CSF-1R, respectively.
A15152

Masitinib mesylate

Masitinib mesylate is a novel inhibitor for Kit and PDGFR??/?? with IC50 of 200 nM and 540 nM/800 nM, weak inhibition to ABL and c-Fms.
A11753

MK-2461

MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
A15182

N-Desethyl Sunitinib

N-desethyl sunitinib is a major and pharmacologically active metabolite of sunitinib, which is potent, ATP-competitive VEGFR, PDGFR?? and KIT inhibitor (Ki values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR?? and KIT respectively).
A10699

Pazopanib HCl (GW786034)

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A11518

Pazopanib(GW-786034)

Pazopanib is a potent and selective multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit that blocks tumor growth and inhibits angiogenesis.
A13111

R1530

R1530 is a pyrazolobenzodiazepine small molecule with potential antiangiogenesis and antineoplastic activities. R1530 is also a mitosis-angiogenesis inhibitor (MAI) that inhibits multiple receptor tyrosine kinases involved in angiogenesis, such as vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor receptor (PDGFR) beta? FMS-like tyrosine kinase (Flt)-3, and fibroblast growth factor receptor (FGFR) -1, -2.
A10250

Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.
A10880

Sunitinib Malate

Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
A10903

Telatinib (BAY 57-9352)

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases.
A11581

Toceranib (PHA 291639, SU 11654)

Toceranib is a kinase inhibitor with both antitumor and antiangiogenic activity through inhibition of KIT, vascular endothelial growth factor receptor 2, and PDGFRβ.

19 Item(s)

per page

Set Descending Direction